MVN/HVN NAPHTHA MIX Sample Clauses

MVN/HVN NAPHTHA MIX. The Seller undertakes and warrants that the qualities of MVN and HVN supplied and delivered hereunder shall fully comply with the specifications stipulated below: MVN PROPERTY UNIT(S) SPECIFICATION TEST METHOD S.G. at 60Deg F report D 1298 Colour (Saybolt) Min +30 SAYBOLT R.V.P at 37.8 Deg C (PSI) report D 323 Lead (PPB) Max 50 D-3116 Sulphur (PPM) Max 50 D-2622 Paraffins (Vol PCT) report D 1319 Olefins (Vol PCT) Max 1.0 D 1319 Aromatics (VolPCT) report D-1319 ***5%Evap.P.(Deg C) Min 75 D-86 ***95%Evap.P.(Deg C) Max 110 D-86 Vanadium (PPM) Max 1 D-3605 Sodium (PPM) Max 1 X-0000 Xxxxxxx (XXX) Max 10 Xxxxxxx Method, Xxxxx 34 edition, (p 796) Total Chlorine (PPM) Max 1 combustion by IP-243 followed by colorometric determination Mercury (PPB) Max 1** Oxygenated Products (MTBE and/or Max 50 PPM ETBE and/or ethanol and/or methanol) HVN PROPERTY UNIT(S) SPECIFICATION TEST METHOD S.G. at 60Deg F report D 1298 Colour (Saybolt) Min +30 SAYBOLT R.V.P at 37.8 Deg C (PSI) report D 323 Lead (PPB) Max 50 D-3116 Sulphur (PPM) Max 50 D-2622 Paraffins (Vol PCT) report D 1319 Olefins (Vol PCT) Max 1.0 D 1319 Aromatics (VolPCT) max 20 D-1319 N+A (VolPCT) min 50 D-1319 ***5% Evap P.(Deg C) Min 90 D-86 ***95 Evap P.(Deg C) Max 155 D-86 Vanadium (PPM) ` Max 1 D-3605 Sodium (PPM) Max 1 X-0000 Xxxxxxx (XXX) Max 10 Xxxxxxx Method, Xxxxx 34 edition, (p 796) Total Chlorine (PPM) Max 1 combustion by IP-243 followed by colorometric determination Mercury (PPB) Max 1**
AutoNDA by SimpleDocs

Related to MVN/HVN NAPHTHA MIX

  • Comverge Comverge hereby represents and warrants the following:

  • HORIZONR Gateway HORIZONR Gateway provides customers with the ability to (i) generate reports using information maintained on the Multicurrency HORIZONR Accounting System which may be viewed or printed at the customer’s location; (ii) extract and download data from the Multicurrency HORIZONR Accounting System; and (iii) access previous day and historical data. The following information which may be accessed for these purposes: 1) holdings; 2) holdings pricing; 3) transactions, 4) open trades; 5) income; 6) general ledger and 7) cash.

  • IMCO IMCO represents and warrants to MFS that (i) the retention of MFS by IMCO as contemplated by this Agreement is authorized by the respective governing documents of the Trust and IMCO; (ii) the execution, delivery and performance of each of this Agreement and the Investment Advisory Agreement does not violate any obligation by which the Trust or IMCO or their respective property is bound, whether arising by contract, operation of law or otherwise; (iii) each of this Agreement and the Investment Advisory Agreement has been duly authorized by appropriate action of the Trust and IMCO and when executed and delivered by IMCO will be a legal, valid and binding obligation of the Trust and IMCO, enforceable against the Trust and IMCO in accordance with its terms, subject, as to enforcement, to applicable bankruptcy, insolvency and similar laws affecting creditors' rights generally and to general equitable principles (regardless of whether enforcement is sought in a proceeding in equity or law); (iv) IMCO is registered as an investment adviser under the Advisers Act; (v) IMCO has adopted a written code of ethics complying with the requirements of Rule 17j-1 under the 1940 Act and that IMCO and certain of its employees, officers and directors are subject to reporting requirements thereunder; (vi) IMCO is not prohibited by the 1940 Act, the Advisers Act or other law, regulation or order from performing the services contemplated by this Agreement; and (vii) IMCO will promptly notify MFS of the occurrence of any event that would disqualify IMCO from serving as investment manager of an investment company pursuant to Section 9(a) of the 1940 Act or otherwise.

  • WHEXXXX xs xxxx of a plan of reorganization, RESTART PARTNERS, L.P., a Delaware Limited Partnership ("Restart"), may acquire an ownership interest in Elsinore Corporation ("Elsinore") or the Four Queens, Inc. ("FQI");

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Xxxxxxxx Tobacco Co the jury returned a verdict in favor of the plaintiff, found the plaintiff to be 30% at fault and RJR Tobacco to be 70% at fault, and awarded $9 million in compensatory damages and $1 million in punitive damages. For a detailed description of the above-described cases, see “— Xxxxx and Xxxxx Progeny Cases” below. In addition, since the end of the third quarter of 2013, jurors returned a verdict in the following Xxxxx Progeny case:

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • Sub-Contracting JHSS may subcontract for the performance hereof, provided, however, that (a) upon engagement of any such subcontractor, and at least annually thereafter, JHSS discloses to the Board the financial terms of such subcontract and a summary of the services provided to the Fund pursuant to such subcontract, and (b) JHSS shall be as fully responsible to the Fund for any acts or omissions of any such subcontractor as JHSS is for its own acts and omissions.

  • API A. Reliant shall supply to Cardinal Health for Manufacturing and Packaging, at Reliant’s sole cost, the API and applicable reference standards in quantities sufficient to meet Reliant’s requirements for each Product as further set forth in Article 4. Prior to delivery of any of the API or reference standard to Cardinal Health for Manufacturing and Packaging, Reliant shall provide to Cardinal Health a copy of the API Material Safety Data Sheet (“MSDS”), as amended, and any subsequent revisions thereto. Reliant shall supply the API, reference standards, and Certificate of Analysis FOB the Facility no later than thirty (30) days before the scheduled Manufacture Date upon which such API will be used by Cardinal Health. Upon receipt of the API, Cardinal Health shall conduct identification testing of the API. Cardinal Health shall use the API solely and exclusively for Manufacturing and Packaging under this Agreement. The maximum volume of API that Reliant supplies to Cardinal Health shall not exceed the amount reflected in the Firm Commitment and the next six (6) months of the Rolling Forecast.

  • Manufacturing and Supply Genentech shall be responsible for manufacturing and supplying Licensed Products for clinical use and commercial sale in the Genentech Field.

Time is Money Join Law Insider Premium to draft better contracts faster.